Martin Duddy

Somatosensory and motor cortical evoked potentials in the diagnosis and management of scan-negative myelopathy

Beatriz I. E. Madureira, Anderson Brito Da Silva, Mathew Elameer, Charles Fry et autres

gb, pt (code pays fourni par la source)

Effect of repurposed simvastatin on disability progression in secondary progressive multiple sclerosis (MS-STAT2): a phase 3, randomised, double-blind, placebo-controlled trial

Jeremy Chataway, Thomas E. Williams, James Blackstone, Nevin A. John et autres

BACKGROUND: Despite the success of immune modulation in the treatment of relapsing multiple sclerosis, disability progression is a major problem driven by multiple mechanisms. Comorbidities (eg, vascular risk) and ageing are thought to augment these neurodegenerative pathologies. In the phase 2b MS-STAT …

gb (code pays fourni par la source)

Evaluating the effectiveness of simvastatin in slowing the progression of disability in secondary progressive multiple sclerosis: a synopsis of MS-STAT2, a multicentre, randomised controlled, double-blind, phase 3 clinical trial

Thomas E. Williams, James Blackstone, Nevin A. John, Marie Braisher et autres

Background Despite the relative success of immuno-modulatory disease-modifying therapy in relapsing remitting multiple sclerosis, progressive worsening of disability remains a major problem, particularly for those with secondary progressive multiple sclerosis. Various underlying mechanisms are likely to contribute, augmented by comorbidities (such as …

gb (code pays fourni par la source)

Evaluating the effectiveness of simvastatin in slowing the progression of disability in secondary progressive multiple sclerosis (MS-STAT2): protocol for a multicentre, randomised controlled, double-blind, phase 3 clinical trial in the UK

James Blackstone, Thomas E. Williams, Jennifer M. Nicholas, Ekaterina Bordea et autres

INTRODUCTION: There remains a high unmet need for disease-modifying therapies that can impact disability progression in secondary progressive multiple sclerosis (SPMS). Following positive results of the phase 2 MS-STAT study, the MS-STAT2 phase 3 trial will evaluate the efficacy and cost-effectiveness of …

gb (code pays fourni par la source)

Patient selection and outcome of deep brain stimulation for multiple sclerosis-associated tremor

Menaka Pasangy Paranathala, Russell Mills, Priya Rai, Nicola Pavese et autres

INTRODUCTION: Tremor is a disabling symptom of multiple sclerosis (MS), with limited treatment modalities. Thalamic ventral-intermediate-nucleus (VIM) deep brain stimulation (DBS) is a method of neuromodulation. We describe the long-term outcomes of our carefully selected patients who underwent VIM DBS for their …

gb (code pays fourni par la source)

Patient-reported outcomes in multiple sclerosis: a prospective registry cohort study

Annalaura Lerede, Jeff Rodgers, Rod Middleton, Adam Hampshire et autres

Abstract Registries have the potential to tackle some of the current limitations in determining the long-term impact of multiple sclerosis. Online assessments using patient-reported outcomes can streamline follow-up enabling large-scale, long-term, cost-effective, home-based, and patient-focused data collection. However, registry data are sparsely …

gb (code pays fourni par la source)

040 Service evaluation of acute neurology referrals in the regional neuroscience centre

Alexander Grundmann, Martin Duddy, Kirstie N. Anderson, Yi Shiau Ng

Background Neurological disorders account for 20% of acute medical admissions and 7% of GP consulta- tions. We evaluated our acute neurology service with the catchment area of 3 million people. Moreover, we investigated the impact on the service during the COVID19 pandemic. …

gb (code pays fourni par la source)

035 Diagnosis of secondary progressive multiple sclerosis in UK centres: results from the SPECTRUM project

Martin Duddy, Carmel Wilkinson, Katherine Rhys, Steve Medhurst

Background As new treatment approaches emerge for progressive forms of multiple sclerosis (MS), it is important to understand the factors underlying current practice. Methods We used a structured questionnaire to interview 59 healthcare professionals (HCPs) from geo- graphically-dispersed UK MS centres about …

gb, fr (code pays fourni par la source)

037 Treating secondary progressive multiple sclerosis in the UK: use of guidelines and stopping criteria

Martin Duddy, Carmel Wilkinson, Katherine Rhys, Steve Medhurst

Background As new treatment approaches emerge for progressive forms of multiple sclerosis (MS), it is important to understand the factors underlying current practice. Methods We used a structured questionnaire to interview 59 healthcare professionals (HCPs) from geo- graphically-dispersed UK MS centres about …

gb (code pays fourni par la source)

Stick or twist? Cost-effectiveness of siponimod compared with continuing existing disease-modifying therapies in the treatment of active secondary progressive multiple sclerosis in the UK

Stephen Montgomery, F Woodhouse, Umakanth Vudumula, Kapil Gudala et autres

OBJECTIVE: Identification of the phenotypic transition from relapsing-remitting multiple sclerosis (RRMS) to secondary progressive multiple sclerosis (SPMS) is often delayed due to disease complexity and an unwillingness to withdraw RRMS disease-modifying therapies (DMTs), driven by limited SPMS treatment options. Despite the paucity …

gb, ie, in (code pays fourni par la source)

Delivering an advice and guidance service in neurology

Kirstie N. Anderson, Naomi Warren, Martin Duddy, Paul G. McKean et autres

It is increasingly common for secondary care to provide advice to primary care without an outpatient appointment. Even before the increased telemedicine during COVID-19, many hospital services gave advice alone for some referrals, yet there are few published data about patient outcomes. …

gb (code pays fourni par la source)

Transition to secondary progressive multiple sclerosis: The consequences for patients and healthcare systems, a healthcare professional survey

Sophie Clare Laura Caseby, F Woodhouse, Stephen Montgomery, Michel Kroes et autres

BACKGROUND AND AIMS: Transition to secondary progressive multiple sclerosis (SPMS) from relapsing-remitting MS (RRMS) is an expected part of the disease trajectory for most patients. However, the transition is challenging to identify due to the gradual nature of progression, and the complications …

gb (code pays fourni par la source)